Capsular Polysaccharide Segment Held Largest Share of Typhoid Fever Vaccines Market during forecast period

According to a new market research study of “Europe Typhoid Fever Vaccines Market Forecast to 2027 - Covid-19 Impact and Analysis by Vaccine Type and Route Of Administration,” Europe typhoid fever vaccines market is projected to reach US$ 145.36 million in 2027 from US$ 74.43 million in 2019. The market is estimated to grow at CAGR of 9.6% from 2020 to 2027. The report highlights trends prevailing in the Europe typhoid fever vaccines market and the factors driving market along with those that act as hindrances.

The typhoid fever vaccines market, based on vaccine type, is further segmented into live attenuated vaccine, capsular polysaccharide vaccines, conjugate vaccine, and others. The capsular polysaccharide vaccines segment held the largest share of the market in 2019, whereas the live attenuated vaccine segment is anticipated to register the highest CAGR of in the market during the forecast period. Polysaccharide (PS) vaccines are antibacterial vaccines with unique characteristics and their main advantage is simplicity of production and high effectiveness against the bacteria.

Europe typhoid fever vaccines market is expected to grow owing to key factor increase in number of EU citizens travelling outside Europe and presence of major market players in the Europe. However, side effects associated with typhoid fever vaccines is likely to have a negative impact on the growth of the market in the coming years.

Leading companies operating in the Europe typhoid fever vaccines market are Sanofi, GlaxoSmithKline plc, Paxvax Inc, Prokarium Ltd., and Scandinavian Biopharma among others.

The report segments Europe Typhoid Fever Vaccines market as follows:

By Vaccine Type

• Live Attenuated Vaccine
• Capsular Polysaccharide Vaccines
• Conjugate Vaccine
• Others

By Route of Administration

• Oral
• Injectable

By Country

• Italy
• Spain
• UK
• France
• Germany